• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Becton Dickinson and Company

    3/18/25 4:33:03 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001945298
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    BECTON, DICKINSON AND COMPANY
    SEC File Number
    001-04802
    Address of Issuer
    1 BECTON DRIVE
    FRANKLIN LAKES
    NEW JERSEY
    07417
    Phone
    2018476800
    Name of Person for Whose Account the Securities are To Be Sold
    RICHARD BYRD
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    459104573.9728713542103/18/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/01/2024Previously Exercised Stock OptionsIssuer Checkbox not checked45909/01/2024Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    10b5-1 Sales for RICHARD BYRD
    1 BECTON DRIVE
    FRANKLIN LAKES � NJ � 07417
    Common03/12/20251940436325.40

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/18/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    12/11/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Richard Byrd

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $BDX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    5/1/2025Outperform → Mkt Perform
    William Blair
    10/1/2024$255.00 → $275.00Neutral → Buy
    Citigroup
    More analyst ratings

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

      For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

      11/23/21 3:16:12 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

      For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

      7/23/21 4:06:11 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    SEC Filings

    See more
    • SEC Form 425 filed by Becton Dickinson and Company

      425 - BECTON DICKINSON & CO (0000010795) (Subject)

      7/14/25 5:25:44 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 425 filed by Becton Dickinson and Company

      425 - BECTON DICKINSON & CO (0000010795) (Subject)

      7/14/25 5:13:03 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 425 filed by Becton Dickinson and Company

      425 - BECTON DICKINSON & CO (0000010795) (Subject)

      7/14/25 5:11:40 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & President, Medical Garrison Michael David exercised 6,360 shares at a strike of $147.68, returned $933,001 worth of shares to the company (5,175 units at $180.29) and sold $213,645 worth of shares (1,185 units at $180.29) (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      7/22/25 5:29:46 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • EVP & President Connected Care Muhsin Bilal was granted 12,221 shares (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      7/7/25 4:21:45 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • New insider Muhsin Bilal claimed no ownership of stock in the company (SEC Form 3)

      3 - BECTON DICKINSON & CO (0000010795) (Issuer)

      7/7/25 4:19:55 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

      4 - BECTON DICKINSON & CO (0000010795) (Issuer)

      2/10/25 5:03:18 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Becton Dickinson downgraded by Citigroup with a new price target

      Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

      5/22/25 8:18:13 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

      5/2/25 8:06:47 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Becton Dickinson downgraded by Goldman with a new price target

      Goldman downgraded Becton Dickinson from Buy to Neutral and set a new price target of $192.00

      5/2/25 8:06:36 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test

      New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Veritor™ System for SARS-CoV-2, a digital test designed to detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors' offices, urgent care centers, retail clinics and other convenient points of care. The BD Veritor™ System fo

      7/30/25 6:50:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

      FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics.  The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants s

      7/23/25 6:50:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD Board Declares Dividend

      FRANKLIN LAKES, N.J., July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on September 30, 2025 to holders of record on September 8, 2025. The indicated annual dividend rate is $4.16 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that he

      7/22/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    See more
    • BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

      FRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.

      7/7/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • BD Names Gregory J. Hayes to Board of Directors

      FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f

      3/27/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

      SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

      12/5/24 4:05:00 PM ET
      $BDX
      $FTRE
      $MRVI
      Medical/Dental Instruments
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations

    $BDX
    Financials

    Live finance-specific insights

    See more
    • BD Board Declares Dividend

      FRANKLIN LAKES, N.J., July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on September 30, 2025 to holders of record on September 8, 2025. The indicated annual dividend rate is $4.16 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that he

      7/22/25 4:15:00 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

      Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growthCreates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brandsAnticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five  Delivers a

      7/14/25 6:15:00 AM ET
      $BDX
      $WAT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • BD Reports Second Quarter Fiscal 2025 Financial Results

      Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organicGAAP and adjusted diluted EPS of $1.07 and $3.35, respectivelyCompany updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025. "Amid a difficult operating environment impacting near-term organic revenue growth, our Q2 results reflect the strength of our business model and ability to exceed our earnings expectations through quality gross margin improvement," s

      5/1/25 6:30:00 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/16/24 4:29:42 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/14/24 10:02:59 AM ET
      $BDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

      SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

      2/13/24 5:00:53 PM ET
      $BDX
      Medical/Dental Instruments
      Health Care